Expression and Functional Analysis of Human Mutated Relaxin-2

CSEF · 2013 Pharmacology/ Toxicology

Overview

Objectives/Goals In this project we attempt to design and obtain in Pichia pastoris a functional recombinant human Relaxin-2 with mutations reducing the binding specificity toward RXFP2, but preserving the binding to RXFP1, for pharmaceutical purposes. Methods/Materials Pichia pastoris was induced by 3% Methanol, with cell density at 30~35 OD600nm, and for 24 hours. Proteins in the supernatant were separated by SDS-PAGE was detected on the membrane using a specific anti-His antibody. The protein was purified through a TALON column. The purified protein was then cleaved by thrombin to produce the mature mutated human Relaxin-2 protein. The CHO cells were transfected with empty vector or the vectors carrying RXFP1 or RXFP2 gene by lipofectamine. Recombinant mutated human Relaxin-2 was added to the cells with a final concentration of 1nM. The cAMP was detected by ELISA. Results 1. Recombinant mutated human Relaxin-2 can be expressed and secreted in the Pichia pastoris system. 2. The purity of recombinant mutated human Relaxin-2 is over 98% after affinity purification. 3. Under the physiological concentration, 1mM recombinant mutated human Relaxin-2 can significantly activate RXFP1 receptor resulting in an accumulation of cAMP. However, there is not obvious difference of the RXFP2 expressed cells and Control cells in cAMP level. Conclusions/Discussion In this study, we successfully expressed and purified a mutated human Relaxin-2 from Pichia pastoris. This mutated human Relaxin-2 can significantly activate the cells with expression of RXFP1 receptor, but not RXFP2, suggesting selective activation of RXFP1 by the mutated Relaxin-2. However, our study does not provide direct ligand-receptor binding evidence thus we cannot exclude the binding possibility between the mutated human Relaxin-2 and RXFP2. Addressing this question and examining the cardioprotective functions of the mutated human Relaxin-2 in animal models will be our next focus.

Summary statement

It have designed and produced a mutated human Relaxin-2 that preferrally activates RXFP1

Help received

Used lab at Newcca corporation under the supervision of Dr. Wenbin Tan

Competition history

  • CSEF 2013 Pharmacology/ Toxicology · Entry S1728

Resources

Related projects

Closest projects by meaning, across every fair and year in the corpus.

Browse more like this

Source: California Science & Engineering Fair public projects

Save projects to your library

Sign in with Google to keep track of projects you find interesting, organized into folders. An account also raises your daily allowance for “Has this been done?”, and lets you create a key for the MCP server with a much higher limit than anonymous use. Browsing stays public.

Continue with Google